Leerink Partnrs Increases Earnings Estimates for Amedisys

Amedisys, Inc. (NASDAQ:AMED) – Research analysts at Leerink Partnrs raised their FY2026 earnings per share estimates for Amedisys in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now forecasts that the health services provider will post earnings per share of $5.06 for the year, up from their prior estimate of $4.53. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The firm had revenue of $587.67 million for the quarter, compared to the consensus estimate of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.98 earnings per share.

Amedisys Stock Up 0.5 %

NASDAQ:AMED opened at $92.59 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market cap of $3.03 billion, a PE ratio of 36.74, a PEG ratio of 1.82 and a beta of 0.73. Amedisys has a 52-week low of $82.15 and a 52-week high of $98.95. The stock has a 50-day simple moving average of $89.47 and a 200 day simple moving average of $93.89.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AMED. Bank of Montreal Can boosted its position in Amedisys by 146.4% during the second quarter. Bank of Montreal Can now owns 10,429 shares of the health services provider’s stock valued at $966,000 after purchasing an additional 6,197 shares during the last quarter. Algert Global LLC acquired a new position in Amedisys during the second quarter valued at approximately $302,000. Creative Planning boosted its position in Amedisys by 7.4% during the second quarter. Creative Planning now owns 4,295 shares of the health services provider’s stock valued at $394,000 after purchasing an additional 295 shares during the last quarter. Cetera Investment Advisers boosted its position in Amedisys by 26.5% during the second quarter. Cetera Investment Advisers now owns 22,778 shares of the health services provider’s stock valued at $2,091,000 after purchasing an additional 4,773 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in Amedisys by 2,159.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 27,200 shares of the health services provider’s stock valued at $2,497,000 after purchasing an additional 25,996 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.